| Fiscal Year End | Company Status | Exempt Flag |
| December 31 | Trading | N |
|
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 18/May/2007 | | Canada | | |
|
|
| Exchange Filing Office |
| Location |
| Montreal Regional Service Office |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| Research and Development in the Physical, Engineering and Life Sciences
| From News Release May 1, 2013 - Immunovaccine Inc. applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company's DepoVax(TM) platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax(TM)-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious diseases pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at www.imvaccine.com.
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| IMV | Immunovaccine Inc. | TSX Venture | TRADING |
|
|
| Name History | From | To |
| Immunovaccine Inc. | 5/Oct/2009 | Present |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2012 CFR | Not Received |
|
|
|
|
|
